INTI · ISSUER CIK 1042418
Inhibitor Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Inhibitor Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Aug 4, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 202621:03 | Jul 1, 2026 | INTI | 10% Owner · +1 joint | G · GiftLate 34d | — | −3,200,000 | 19,901,057 | -14% | — | ||
| Aug 4, 202613:33 | May 4, 2026 | INTI | Director, 10% Owner · +1 joint | A · GrantLate 92d | — | +50,000 | 23,614,985 | +0% | — | ||
| Aug 4, 202612:19 | May 4, 2026 | INTI | Director | A · GrantLate 92d | — | +50,000 | 1,221,271 | +4% | — | ||
| Aug 4, 202612:15 | May 4, 2026 | INTI | Director | A · GrantLate 92d | — | +50,000 | 1,229,543 | +4% | — | ||
| Aug 4, 202611:55 | May 4, 2026 | INTI | Chief Executive Officer, Director, 10% Owner | A · GrantLate 92d | — | +50,000 | 150,000 | +50% | — |